HGS shares slide ahead of Benlysta panel
This article was originally published in Scrip
Human Genome Sciences saw its share price drop on 12 November as the market responded to the publication of briefing documents ahead of the 16 November US FDA arthritis advisory panel convened to consider the company's lupus candidate Benlysta (belimumab). In the briefing documents, the FDA is questioning whether the benefits of the human anti-Blys (B lymphocyte stimulator protein) monoclonal antibody outweigh the risks of its use.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.